Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neurofibromatosis 2 × aflibercept × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 2 Brain Neoplasms 2 Astrocytoma 2 Uterine Cervical Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Small Cell Lung Carcinoma 1 Oligodendroglioma 1 Neurofibromatosis 2 1 Melanoma 1 Macular Degeneration 1 Gliosarcoma 1 Glioma 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma, Merkel Cell 1

Interventions

Bevacizumab 5 Everolimus 4 Sirolimus 2 Lapatinib 2 temsirolimus 1 neratinib 1 icotinib 1 emvododstat 1 brolucizumab 1 brigatinib 1 aflibercept 1 Vascular Endothelial Growth Factor A 1 Valproic Acid 1 Sunitinib 1 Magnetic Resonance Imaging 1 Immunoglobulin G 1 HDAC-42 1 Exome 1 Endostatins 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Axitinib 1 Aspirin 1 AZD 6244 1 89Zr-bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡